![]() Eli Lilly Prepares to Launch New Weight Loss Pill by Early 2026To Be Taken Orally!Eli Lilly & Co., a leading pharmaceutical company, is gearing up to release a new weight loss pill, Orforglipron, expected to receive FDA approval as early as early 2026. This new drug aims to provide a convenient oral alternative to the current injectable treatments dominating the market, such as Lilly's own Zepbound and Novo Nordisk's Wegovy. CEO David Ricks announced that orforglipron has shown promising results in mid-stage trials, helping patients lose up to 14.7% of their body weight, compared to just 2.3% among those who took a placebo. The pill is designed to be more convenient for patients and easier to manufacture, addressing the challenges faced with injectable forms. ![]() Lilly's foray into the weight loss drug market comes at a time when demand for such treatments is soaring. The company is competing with Novo Nordisk and other rivals to capture a significant share of this booming market. With the potential to simplify weight loss treatment, orforglipron could revolutionize the way obesity is managed. As Lilly prepares for the release of late-stage trial data by mid-2025, the anticipation around Orforglipron continues to grow. If approved, this pill could offer a much-needed alternative for those seeking effective weight loss solutions without the hassle of injections. |
Membership includes access to our member area where you will find the Five Crucial Factors, private pages, member library, 30 day email training and more.
Presently, membership is free and once you join, it will remain free.
Advertisement: